Bundamedik Tbk PT (BMHS) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Bundamedik Tbk PT IDR 101, price IDR 200, upside -49.3%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bundamedik Tbk PT for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
PT Bundamedik Tbk provides health care services in Indonesia.
Show more
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, and dental clinic services management consulting businesses. It also provides fertility clinic, and oncology; emergency services; laboratory, radiology, and IVF services; and genomics and clinical pathology laboratory, and corporate health services. In addition, the company operates a BMHS nurse center, bunda neuro centre, bunda heart centre, bunda urology centre, digital substraction angiography, RSM oncology, and advanced robotic minimal invasive surgery. PT Bundamedik Tbk was founded in 1961 and is based in Jakarta Pusat, Indonesia. PT Bundamedik Tbk is a subsidiary of PT Bunda Investama Indonesia.
Stock analysis
Bundamedik Tbk PT (BMHS) currently trades at 200.00 IDR, while our model-based Fair Value estimate is 101.49 IDR, implying the stock looks roughly 97.1% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 151.85 IDR per share, and 4 of the 23 models we run sit above the 200.00 IDR price.
Bear case: the Growth Earnings group reads lowest at 26.96 IDR, and 19 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: 83.51 IDR (bear) to 101.49 IDR (bull), the price of 200.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bundamedik Tbk PT reported revenue of 1.6T IDR in FY2025 versus 1.7T IDR in FY2021, a compound −1.4%/yr. Reported net income was 12.4B IDR in FY2025, compounding −55.5%/yr from FY2021.
Key figures
Market cap 1.5T IDR (≈ $83.4M) · P/E ratio 192.3 · P/S ratio 1.48 · EPS (TTM) 1.04 IDR · Net margin 0.8% · Return on equity 1.1% · Return on assets (EBIT) 6.2% · Operating margin 3.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −49%, BMHS screens richer than that median.
Fair Value models
Bear 83.51 IDRFair Value 101.49 IDRBull 101.49 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.7636 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−34.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−34.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 7%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+44.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +40.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−49% · Bottom 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets1% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)4% · Bottom 25%
Growth and dividend
Revenue growth−2% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.37× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)192.3× · Priciest 25%
P/B0.77× · Cheaper than median
P/S (TTM)0.93× · Cheaper than median
P/FCF0.0× · Cheapest 25%
EV/EBITDA8.6× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 28
PAST (return on equity)4· sector 31
HEALTH (low debt)82· sector 89
DIVIDEND (yield)0· sector 43
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bundamedik Tbk PT (BMHS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 101.49 IDR versus a price of 200.00 IDR, about −49% upside (overvalued).
What is the fair value of BMHS?
Our model-based fair value for Bundamedik Tbk PT is 101.49 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 200.00 IDR.
What is the quality score of BMHS?
Bundamedik Tbk PT has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bundamedik Tbk PT (BMHS)?
Our model-based price target is the fair value of 101.49 IDR (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 83.51 IDR, optimistic scenario 101.49 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Bundamedik Tbk PT stock forecast for 2026?
Our models put fair value at 101.49 IDR, about −49% upside versus a price of 200.00 IDR (overvalued). Cautious scenario 83.51 IDR, optimistic scenario 101.49 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Bundamedik Tbk PT (BMHS)?
Bundamedik Tbk PT reported trailing-twelve-month revenue of about 1.6T IDR (latest available figure, as of Sep 24, 2026).
What growth is priced into Bundamedik Tbk PT (BMHS)?
For today's price to be fair in a discounted-cash-flow model, Bundamedik Tbk PT would have to grow free cash flow by +44.6 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BMHS use?
Our models discount Bundamedik Tbk PT at 15.0 %: a base by market capitalisation (micro), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bundamedik Tbk PT that is +44.6 % per year a year over ten years, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Bundamedik Tbk PT (BMHS) delivered so far?
Over the past 5 years revenue at Bundamedik Tbk PT grew +7.1 % a year. The price currently implies +44.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bundamedik Tbk PT (BMHS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bundamedik Tbk PT (+44.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bundamedik Tbk PT (BMHS)?
The free-cash-flow yield on the price is 2.13 %: that much free cash flow Bundamedik Tbk PT produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bundamedik Tbk PT (BMHS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bundamedik Tbk PT it is 101.49 IDR per share (as of Sep 24, 2026), against a price of 200.00 IDR. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Bundamedik Tbk PT stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BMHS trades above its calculated fair value: price 200.00 IDR, fair value 101.49 IDR, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMHS?
No. The price is what the market pays today (200.00 IDR); the fair value is what the company's own numbers justify (101.49 IDR). For Bundamedik Tbk PT the two are 98.51 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Bundamedik Tbk PT worth?
The market values Bundamedik Tbk PT at about 1.5T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 200.00 IDR; our models calculate a fair value of 101.49 IDR per share.
What do the bullish and bearish scenarios say about BMHS?
Our models span a range for Bundamedik Tbk PT: cautious scenario 83.51 IDR, base 101.49 IDR, optimistic 101.49 IDR per share (as of Sep 24, 2026, price 200.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BMHS?
Bundamedik Tbk PT trades at a price-to-earnings ratio of 192.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 101.49 IDR is built from several models across several years. Other multiples: P/B 0.8, P/S 0.9, EV/EBITDA 8.6.
How solid is the balance sheet of Bundamedik Tbk PT (BMHS)?
Balance-sheet figures for Bundamedik Tbk PT (as of Sep 24, 2026): return on equity 1.1%, debt of 0.37 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is BMHS from its 52-week high?
Bundamedik Tbk PT trades at 200.00 IDR, about 11% below its 52-week high of 224.69 IDR and 37% above the low of 146.15 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 101.49 IDR is for.
Which stocks are comparable to Bundamedik Tbk PT?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bundamedik Tbk PT stock attractive at the current price?
The data as of Sep 24, 2026: price 200.00 IDR, calculated fair value 101.49 IDR (−49%), Quality Score 46/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMHS calculated?
We run Bundamedik Tbk PT through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 101.49 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Bundamedik Tbk PT itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bundamedik Tbk PT (BMHS)?
The closing price on Sep 24, 2026 was 200.00 IDR. Our model-based fair value is 101.49 IDR, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bundamedik Tbk PT right now?
The price sits above even our optimistic bull case (101.49 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Bundamedik Tbk PT
How large is the market capitalisation of Bundamedik Tbk PT (BMHS)?
The market capitalisation of Bundamedik Tbk PT is 1.5T IDR (≈ $83.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bundamedik Tbk PT (BMHS)?
The price-to-sales ratio of Bundamedik Tbk PT is 1.48 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bundamedik Tbk PT (BMHS)?
Earnings per share at Bundamedik Tbk PT are 1.04 IDR (price ÷ EPS = P/E 192.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bundamedik Tbk PT (BMHS)?
The net margin of Bundamedik Tbk PT is 0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bundamedik Tbk PT (BMHS)?
The return on equity (ROE) of Bundamedik Tbk PT is 1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bundamedik Tbk PT (BMHS)?
On an EBIT basis the return on assets of Bundamedik Tbk PT is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bundamedik Tbk PT (BMHS)?
The operating margin of Bundamedik Tbk PT is 3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bundamedik Tbk PT (BMHS)?
Revenue at Bundamedik Tbk PT is growing −2.1% versus a year earlier (3y avg −0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bundamedik Tbk PT (BMHS)?
Earnings per share at Bundamedik Tbk PT are growing −98.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bundamedik Tbk PT (BMHS) carry?
The net debt of Bundamedik Tbk PT is 529B IDR (fiscal year 2025, ≈ 16.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bundamedik Tbk PT in the live analysis
One click puts Bundamedik Tbk PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
